What Is 5-Amino-1MQ? A Research Guide to the NNMT Inhibitor

5-Amino-1MQ appears in almost every research-peptide catalogue in Canada, and in most of them it is filed under "peptides." It is not one. 5-Amino-1-methylquinolinium is a small-molecule quinolinium compound — a single fused ring system with a methylated nitrogen, molecular weight around 159 g/mol, CAS 42464-96-0 for the iodide salt. There is no amide backbone, no amino acid sequence, nothing that makes a peptide a peptide.

This is not pedantry. The distinction determines how the compound behaves, how it is handled, and why it shows up in research contexts where peptides cannot go.

What NNMT actually does

5-Amino-1MQ is studied as an inhibitor of nicotinamide N-methyltransferase, usually shortened to NNMT. That enzyme takes nicotinamide — the precursor your cells use to build NAD+ — and methylates it into 1-methylnicotinamide, which is then excreted. Every molecule of nicotinamide that goes down that path is one that does not become NAD+.

NNMT is expressed at low levels in most tissues but is markedly elevated in white adipose tissue in obese models, and elevated again in several tumour types. The research question that follows is a straightforward one: if you inhibit the enzyme, does the nicotinamide pool redirect toward NAD+ synthesis, and does that change cellular energy metabolism in the tissue where the enzyme was overexpressed?

What the published research reports

Three papers anchor most of the literature. Kraus and colleagues (2014) used antisense oligonucleotide knockdown of NNMT in diet-induced obese mice and reported protection against weight gain along with improved insulin sensitivity — establishing NNMT as a metabolic target before any small-molecule inhibitor existed (PMID 24856135).

Neelakantan and colleagues (2017) developed membrane-permeable small-molecule NNMT inhibitors — the class 5-Amino-1MQ belongs to — and reported reduced adiposity in the same diet-induced obesity model (PMID 28211672). Kannt and colleagues (2018) extended the work with a separate inhibitor series against metabolic syndrome endpoints (PMID 29730990).

Two things are worth stating plainly about this body of work. It is preclinical, conducted in rodent models. And the compound most often studied is not always 5-Amino-1MQ specifically but other members of the same inhibitor class — the mechanism is better characterised than this individual molecule.

Why it keeps getting called a peptide

Three reasons, and none of them are good ones. It is sold by the same suppliers who sell peptides. It arrives as a lyophilized powder in a vial, which is what peptides look like. And the research it sits alongside — NAD+ work, metabolic work — overlaps heavily with peptide research.

The practical consequence is that buyers apply peptide assumptions to it. Some of those assumptions are harmless. One is not: peptides are destroyed by gastric proteases, which is why they are studied parenterally. 5-Amino-1MQ has no peptide bonds to cleave, which is exactly why oral formulations of it exist and why "5-amino-1mq capsules" is a real search query while "BPC-157 capsules" is mostly a scam signal.

Oral versus injectable, and what that means for the vial

Because the molecule survives the gut, both routes appear in the literature and both appear on the market. The vialled lyophilized form that research suppliers sell is the one used where precise, verified concentration matters — you know exactly what is in the vial because the batch was assayed, and you set the concentration yourself on reconstitution.

Capsule products, by contrast, are usually sold as supplements, which in Canada means no batch assay is published and the actual content is whatever the filler decided. If the reason for using a research-grade supplier is analytical certainty, the vial is the format that delivers it.

What "dosage" means in the literature

Searches for 5-Amino-1MQ dosage are among the most common in this topic, and the honest answer is that the published figures are animal-model figures. Studies in the NNMT inhibitor class have typically administered on a mg/kg basis to mice over multi-week periods. Those numbers do not convert to a human protocol by simple body-weight scaling, and no controlled human dosing study has established one.

What a researcher can control is concentration. A 50mg vial reconstituted with 2mL of bacteriostatic water gives 25mg/mL; with 5mL it gives 10mg/mL. The vial size determines your working range and your cost per milligram — a 50mg vial at bulk pricing runs materially cheaper per milligram than a 10mg vial, which is the entire reason the larger format exists.

Handling and storage

• Sealed and lyophilized: 2–8°C protected from light. For storage beyond a few months, −20°C.

• Reconstitution: bacteriostatic water, added slowly down the vial wall rather than directly onto the powder.

• After reconstitution: refrigerated at 2–8°C, used within an appropriate research timeframe. Solutions have a materially shorter usable life than sealed lyophilized material.

• Verification: a batch without a COA you can independently confirm is a batch of unknown identity. This matters more for a compound routinely mislabelled at the category level.

Is 5-Amino-1MQ a peptide?

No. It is a small-molecule quinolinium NNMT inhibitor with no amino acid sequence and no peptide bonds. It is commonly catalogued alongside peptides because it is sold by the same suppliers and supplied in the same lyophilized vial format.

What does 5-Amino-1MQ do?

It is studied as an inhibitor of nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and diverts it away from NAD+ synthesis. Research interest centres on what happens to cellular energy metabolism in tissues where that enzyme is overexpressed, particularly white adipose tissue in obese models.

What is the difference between the 10mg and 50mg vials?

Quantity of lyophilized material only. Both are the same compound held to the same purity standard and the same batch testing. The 50mg vial substantially lowers cost per milligram for longer protocols.

Does 5-Amino-1MQ work?

The preclinical evidence for NNMT inhibition as a metabolic mechanism is reasonably developed in rodent models. Evidence for this specific molecule in humans does not exist in controlled form. Anyone claiming otherwise is describing anecdote, not data.

Is it available in Canada?

Yes. Durham Peptides stocks 5-Amino-1MQ domestically. Orders placed and paid before 5:00 PM EST ship the same business day via Canada Post Xpresspost with full tracking — no customs delays or border holds.